Chargement en cours...
CSIG-26. HETEROGENEITY OF EGFRvIII-POSITIVE GLIOBLASTOMA STEM CELLS: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT
EGFRvIII, a constitutively active mutant of EGFR, is present in over 20% of glioblastoma patients. To develop pre-clinical models for developing therapies against EGFRvIII-expressing GBMs, we isolated four different EGFRvIII-positive (EGFRvIII+) glioblastoma stem cell lines (GSCs). Molecular charact...
Enregistré dans:
| Publié dans: | Neuro Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692932/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.220 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|